Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: Parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity

Psychiatry Research

Volumn 121, Issue 2, 2003, Pages 123-132

  Sirota, Pinkhas ^a,b   Gavrieli, Ronit ^b,c   Wolach, Baruch ^b,c  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

Author keywords

Chemotaxis; Free radicals; Phagocytosis; Reactive oxygen species; Schizophrenia; Superoxide anion

Indexed keywords

ANION; FREE RADICAL; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CELL ACTIVITY; CELL FUNCTION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MALE; NEGATIVE SYNDROME; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTOSIS; POSITIVE SYNDROME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

EID: 0344628603     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(03)00222-1     Document Type: Article

References (65)

1. Altamura A.C., Boin F., Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. European Neuropsychopharmacology. 10:1999;1-4.
2. American Psychiatric Association, 1994. Diagnostic and Statistical Manual for Mental Disorders. Author, Washington, DC.
3. Arvindakshan M., Sitasawad S., Debsikar V., Ghate M., Evans D., Horrobin D.F., Bennet C., Ranjekjar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry. 53:2003;56-64.
4. Arolt V., Rothermundt M., Wandinger K.P., Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry. 5:2000;150-158.
5. Babior B.M. The respiratory burst of phagocytes. Journal of Clinical Investigation. 73:1984;599-601.
6. Biffl W.L., Moore E.E., Moore F.A., Carle V.S., Kim F.J., Franciose R.J. Interleukin-6 potentiates neutrophil priming with platelet-activating factor. Archives of Surgery. 129:1994;1131-1136.
7. Biffl W.L., Moore E.E., Moore F.A., Barnett C.C. Jr., Carl V.S., Peterson V.N. Interleukin-6 delays neutrophil apoptosis. Archives of Surgery. 131:1996;24-29.
8. Boxer L.A. Neutrophil disorders: qualitative abnormalities of the neutrophil. Williams W.J., Beutler E., Erslev A.J., Lichtman M.A. Hematology. Fifth ed :1995;McGraw-Hill, New York.
9. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scandinavian Journal of Clinical and Laboratory Investigation. 21:(Suppl. 97):1963;77.
10. Burg N.D., Pillinger M.H. The neutrophil: function and regulation in innate and humoral immunity. Clinical Immunology. 99:2001;7-17.
11. Cadet J.L. Free radical mechanisms in the central nervous system: an overview. International Journal of Neuroscience. 40:1988;13-18.
12. Clawson C.C., Repline J.E. Quantitation of maximal bactericidal capacity in human neutrophils. Journal of Laboratory and Clinical Medicine. 88:1976;316-327.
13. Cosentino M., Fietta A., Caldiroli E., Marino F., Rispoli L., Cornelli M., Lecchini S., Frigo G. Assessment of lymphocyte subsets and neutrophil leukocyte function in chronic psychiatric patients on long-term drug therapy. Progress in Neuro-psychopharmacology and Biological Psychiatry. 20:1996;1117-1129.
14. Drath D.B., Karnovsky M.I. Superoxide production by phagocytic leukocytes. Journal of Experimental Medicine. 141:1975;257-261.
15. Endicott J., Spitzer R.L. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry. 35:1978;837-844.
16. Falk W., Goodwin R.H. Jr., Leonard E.J. A 48-well microchemotaxis assembly for rapid and accurate measurement of leukocyte migration. Journal of Immunology Methods. 33:1980;239.
17. Firer M., Sirota P., Schild K., Elizur A., Slor H. Anticardiolipin antibodies are elevated in drug free multiply affected families with schizophrenia. Journal of Clinical Immunology. 14:1994;73-78.
18. Frommberger U.H., Bauer J., Haselbauer P., Frailin A., Riemann D., Berger M. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: a comparison between the acute state and after remission. European Archives of Psychiatry and Clinical Neuroscience. 247:1997;228-233.
19. Ganguli R., Yang Z., Shurin G., Changappa K.N., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research. 51:1994;1-10.
20. Horrobin D.F., Manku M.S., Morse-Fisher N., Vaddadi K.S., Courtney P., Glen A.I., Glen E., Spellman M., Bates C. Essential fatty acids in plasma phospholipids in schizophrenia. Biological Psychiatry. 25:1989;562-568.
21. Katanaev V.L. Signal transduction in neutrophil chemotaxis. Biochemistry (Moscow). 46:2001;351-368.
22. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 13:1987;261.
23. Kramer V.H.P., Grimberger J.A., Timmerman H., Bast A. The effects of ischemia and recirculation, hypoxia and recovery on antioxidant factors and β-adrenoreceptor density: is the damage in erythrocytes a reflection of brain damage caused by complete cerebral ischemia and by hypoxia? Biochemical Research Communications. 149:1987;568-575.
24. Leon J.D. Smoking and vulnerability for schizophrenia. Schizophrenia Bulletin. 22:1996;405-409.
25. Lin A., Kenis G., Bingotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpé S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Research. 32:1998;9.
26. Lohr J.B. Oxygen radicals and neuropsychiatric illness, some speculations. Archives of General Psychiatry. 48:1991;1097-1106.
27. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research. 29:1995;141-152.
28. Maes M., Delange J., Ranjan R., Meltzer H.Y., Demyder R., Cooremans W., Scharpé S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Research. 66:1997;1-11.
29. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Research. 19:1996;1-17.
30. Mahadik S.P., Scheffer R.E. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids. 55:1996;45-54.
31. Mahadik S.P., Mulchandani M., Hedge M.V., Ranjekar P.K. Cultural and socioeconomic differences in dietary intake of essential fatty acids and antioxidants: effects on the outcome. Horrobin D., Glen A.L., Peet M. Phospholipid Spectrum Psychiatric Disorders. 1999;167-179 Marius Press, Carnforth, UK.
32. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry. 25:2001;463-493.
33. McAdams C., Leonard B.E. Neutrophil and monocyte phagocytosis in depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry. 17:1993;971-984.
34. Melamed Y., Sirota P., Dicker D.R., Fishman P. Superoxide anion production by neutrophils derived from peripheral blood of schizophrenic patients. Psychiatry Research. 77:1998;29-34.
35. Mukerjee S., Mahadik S.P., Scheffer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophrenia Research. 19:1996;19-26.
36. Müller N., Reidel M., Ackenheil M., Schwarz M.J. The role of immune function in schizophrenia: an overview. European Archives of Psychiatry and Clinical Neuroscience. 249:1999;62-68.
37. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophrenia Research. 20:1996;269-273.
38. Peet M., Langharne J.D., Mellor J., Ramchand C.N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients and the clinical effects of dietary supplementation. Prostaglandins, Leukotrienes and Essential Fatty Acids. 55:1996;71-75.
39. Rapaport M.H., McAllister C.G., Pickar D., Nelson D.L., Paul S.M. Elevated levels of soluble interleukin 2 receptors in schizophrenia. Archives of Genetic Psychiatry. 46:1989;291-292.
40. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes and Essential Fatty Acids. 55:1996;33-43.
41. + flux. Nature. 416:2002;291-297.
42. Richardson J.S. Free radicals in the genesis of Alzheimer's disease. Annals of the New York Academy of Sciences. 695:1993;73-76.
43. Rwegellera G.G., Fernando K.H., Okongo'o O. Bactericidal activity of neutrophils of schizophrenic patients. Medical Journal of Zambia. 16:1982;21-22.
44. Schattner A., Cori Y., Hahn T., Sirota P. No evidence for autoimmunity in schizophrenia. Journal of Autoimmunity. 9:1996;661-666.
45. Segal B.H., Leto T.L., Gallin J.I., Malech H.L., Holland S.M. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine. 79:2000;170-200.
46. Sethi S., Singh M.P., Dikshit M. Nitric oxide-mediated augmentation of polymorphonuclear free radical generation after hypoxia-reoxygenation. Blood. 93:1999;333-340.
47. Shintani F., Kanba S., Mauro N., Nakaki T., Nibuga M., Suzuki E., Kinoshita N., Yagi G. Serum interleukin-6 in schizophrenic patients. Life Sciences. 49:1991;661-664.
48. Sinet P.M. Metabolism of oxygen derivatives in Down's Syndrome. Annals of the New York Academy of Sciences. 396:1982;83-94.
49. Sirota P. Is schizophrenia an autoimmune disease? Israel Journal of Medical Science. 26:1990;694-697.
50. Sirota P., Firer M., Schild K., Barak Y., Zurgil N., Elizur A., Slor H. Increased anti-sm antibodies in schizophrenic patients and their families. Progress in Neuro-psychopharmacology and Biological Psychiatry. 17:1993;793-800.
51. Sirota P., Firer M., Schild K., Tanay A., Elizur A., Meytes D., Slor H. Autoantibodies to DNA in multicase families with schizophrenia. Biological Psychiatry. 33:1993;450-455.
52. Sirota P., Schild K., Elizur A., Djaldetti M., Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Progress in Neuro-psychopharmacology and Biological Psychiatry. 19:1995;75-83.
53. Sirota P., Mosheva T., Reznik I., Elizur A., Hochman A. Altered antioxidant status in schizophrenia and the beneficial effect of vitamin E (Abstract). Biological Psychiatry. 45:(Supplement):1999;43S.
54. Smith R.S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Medical Hypotheses. 39:1992;248-257.
55. Srivastava N., Barthwal M.K., Dalal P.K., Agarwal A.K., Nag D., Srimal R.C., Seth P.K., Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berlin). 158:2001;140-145.
56. Stefanis C.N., Issidrides M.R. Histochemical changes in the blood cells of schizophrenic patients under pimozide treatment. Biological Psychiatry. 11:1976;53-68.
57. Suzuki Y., Leherer R.I. NADPH oxidase activity in human neutrophils stimulated by phorbol myristate acetate. Journal of Clinical Investigation. 66:1980;1049-1418.
58. Weisbart R.H., Golde D.W., Clark S.C., Wong G.G., Gasson J.C. Human granulocyte macrophage colony-stimulating factor is a neutrophil activator. Nature. 314:1985;361-363.
59. Wolach B., Bachner R.L., Boxer L.A. Review: clinical and laboratory approach to the management of neutrophil dysfunction. Israel Journal of Medical Science. 18:1982;897-916.
60. Wolach B., Ben Dor M., Chomsky O., Gavrieli R., Shinitzky M. Improved chemotactic ability of neonatal polymorphonuclear cells induced by mild membrane rigidification. Journal of Leukocyte Biology. 51:1992;324-328.
61. Wolach B., Sonnenschein D., Gavrieli R., Chomsky O., Pomeranz A., Yuli I. Neonatal neutrophil inflammatory responses: parallel studies of light scattering, cell polarization, chemotaxis, superoxide release, and bactericidal activity. American Journal of Hematology. 58:1998;8-15.
62. Wolach B., Gavrieli R., Pomeranz A. Effect of granulocyte and granulocyte macrophage colony stimulating factors (G-CSF and GM-CSF) on neonatal neutrophil functions. Pediatric Research. 48:2000;369-373.
63. Wong C.T., Tsoi W.F., Saha N. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophrenia Research. 22:1996;165-171.
64. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophrenia Research. 32:1998;1-8.
65. Zhelev D.V., Alteraifi A. Signaling in the motility responses of the human neutrophil. Annals of Biomedical Engineering. 30:2002;356-370.